Takeda Pharmaceutical said on Wednesday it will stop its cell therapy initiatives and seek a partner to advance its research ...

Following up on previous, dimly received issuances, a new set of ideas published by the FDA to streamline regulatory pathways ...

Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 ...

Relive Health, one of the nation’s fastest-growing providers of integrative and regenerative care, has partnered with Dr.

The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...

Cancer scientists have been working against the clock for decades to outsmart a disease that comes back more powerfully after treatment. Traditional treatments like chemotherapy, radiation, and even ...

An international workshop of scientists, regulators, and industry experts led by Prof Ivana Barbaric convened to address the risks of genetic mutations in stem cell therapy.

The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while ...

Dr. Christina Cho, a hematologist/oncologist specializing in stem cell transplantation and cellular therapy at Hackensack Meridian Hackensack University Medical Center’s John Theurer Cancer Center, ...

CAR-T cell therapy has cured some children with blood cancers and is being studied in solid tumors, where responses differ ...

Holdin announced the Company will exhibit two posters at the European Society of Gene and Cell Therapy 2025 Annual Congress, which ...

Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action ...